Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

DURHAM, N.C., May 8, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company's improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.

The study, which was published in the May issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests. Investigators found that the improved amplification process resulted in superior protein expression levels and a greater capacity of dendritic cells to induce a strong T-cell response.

"The new RNA amplification techniques we have developed further validate Argos Therapeutics' leadership in the field of RNA-containing therapeutics," said Charles Nicolette , Ph.D., Chief Scientific Officer and Vice President of Research and Development of Argos Therapeutics. "With the ADAPT Phase 3 study for AGS-003 well underway, the improved amplification process should help to provoke stronger immune responses in study patients and ultimately lead to positive clinical outcomes."

By tracking specific antigens, researchers were able to demonstrate that the protein antigens were produced inside dendritic cells transfected with the amplified RNA. It was further shown that RNA amplified using the improved process resulted not only in higher levels of antigen expression but also in greater numbers of antigen-specific memory T cell responses. In a completed Phase 2 study with AGS-003, this specific type of immune res
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... GA (PRWEB) September 18, 2014 Ben ... the Alex Ormond, Jr. Leadership Award by the Savannah ... improving healthcare and wellness throughout the nation and especially ... receive this award,” said Ben. “The Savannah Science Seminar ... 65 years and multiple generations have gone through the ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of Health ... a four-year, $1.3 million grant to the Los Angeles ... research and development of a vaccine to protect patients ... Staphylococcus aureus (MRSA). , The National ... NIH awarded the grant to LA BioMed infectious disease ...
(Date:9/18/2014)... trying to develop tools that would allow them to ... moment a neuron fires to the resulting behavior in ... are working to develop a range of new tools ... one such tool that provides a new way of ... worka collaboration between Viviana Gradinaru (BS ,05), assistant professor ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... Brophy Marcus HealthDay Reporter , WEDNESDAY, Oct. 5 ... after a kidney transplant allows some patients to cast away ... new organ, according to a small new study from the ... in the United States and while they can greatly improve ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 ... tip-top health may have a greater risk of developing dementia ... Oct. 5 issue of the journal Neurology . ... simple tool for doctors to determine a person,s risk of ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- The death toll from ... risen to 18, and a total of 100 people have ... Control and Prevention reported late Tuesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
... from Mount Sinai School of Medicine have found high ... (AGEs) in infants. Excessive food AGEs, through both maternal ... children,s risk for diseases such as diabetes from a ... adults found that cutting back on processed, grilled, and ...
... (HealthDay News) -- Scientists who taught monkeys to use their ... virtual body) and to identify the texture of virtual objects ... for people who,ve suffered crippling spinal injuries. "Someday in ... technology not only to move their arms and hands and ...
... (October 5, 2011)Prostate cancer is the most common cancer ... the second leading cause of cancer-related deaths in this ... their prostate, followed by radiation therapy applied to their ... once situated. The most common technique of ...
Cached Medicine News:Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3Health News:New study shows inflammatory food toxins found in high levels in infants 2Health News:New study shows inflammatory food toxins found in high levels in infants 3Health News:Monkeys Use Brain Power, Not Hands, to 'Move' Virtual Objects 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: